Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.52 |
| ▸ | ESR2 | Q92731 | 9/20 | 0.47 |
| ▸ | ESR1 | P03372 | 5/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | NOS3 | P29474 | 2/20 | 0.40 |
| ▸ | NOS1 | P29475 | 2/20 | 0.40 |
| ▸ | NOS2 | P35228 | 2/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1064153 | 0.95 | SLC18A3 (0.56) | SLC18A3ESR2MEN1MAPTKMT2A | |
| SCHEMBL112829 | 0.92 | SLC18A3 (0.55) | SLC18A3ESR2MEN1MAPTKMT2A | |
| SCHEMBL22291709 | 0.92 | SLC18A3 (0.55) | SLC18A3ESR2MEN1MAPTKMT2A | |
| SCHEMBL7301118 | 0.92 | SLC18A3 (0.55) | SLC18A3ESR2MEN1MAPTKMT2A | |
| SCHEMBL23192020 | 0.92 | SLC18A3 (0.55) | SLC18A3ESR2MEN1MAPTKMT2A | |
| SCHEMBL24096570 | 0.92 | SLC18A3 (0.55) | SLC18A3ESR2MEN1MAPTKMT2A | |
| SCHEMBL21449754 | 0.92 | SLC18A3 (0.55) | SLC18A3ESR2MEN1MAPTKMT2A | |
| SCHEMBL11285130 | 0.90 | SLC18A3 (0.44) | SLC18A3ESR2ESR1CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL4986182 | 0.90 | SLC18A3 (0.53) | SLC18A3MEN1MAPTKMT2AHDAC1 | |
| SCHEMBL1128088 | 0.89 | SLC18A3 (0.50) | SLC18A3ESR2ESR1CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617795-B2 | Substituted 6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidines, 5,7-dihydrofuro[3,4-d]pyrimidines, and pyrido[2,3-d]pyrimidines as KCC2 modulators | ASTRAZENECA AB (SE) | 2026-05-05 | — | — | US | disclosed |
| EP-4695226-A1 | GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR ANTAGONISTS AND USES THEREOF | Pfizer Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| US-12391663-B2 | Isoindolinone compounds | MONTE ROSA THERAPEUTICS AG (CH) | 2025-08-19 | — | — | US | disclosed |
| US-20250115581-A1 | SUBSTITUTED PIPERIDINES AS CK1A DEGRADERS | MONTE ROSA THERAPEUTICS AG (CH) | 2025-04-10 | — | — | US | disclosed |
| CN-119735594-A | Fused pyrimidine compounds as KCC2 modulators | 阿斯利康(瑞典)有限公司 | 2025-04-01 | — | — | CN | disclosed |
| CN-119684300-A | Fused pyrimidine compounds as KCC2 modulators | 阿斯利康(瑞典)有限公司 | 2025-03-25 | — | — | CN | disclosed |
| CN-119684299-A | Fused pyrimidine compounds as KCC2 modulators | 阿斯利康(瑞典)有限公司 | 2025-03-25 | — | — | CN | disclosed |
| WO-2025054339-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS INHIBITORS OF KIT | ARCUS BIOSCIENCES, INC. (US) | 2025-03-13 | — | — | WO | disclosed |
| CN-115298182-B | Fused pyrimidine compounds as KCC2 modulators | 阿斯利康(瑞典)有限公司 | 2025-02-11 | — | — | CN | disclosed |
| US-20240366598-A1 | GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR ANTAGONISTS AND USES THEREOF | PFIZER INC. (US) | 2024-11-07 | — | — | US | disclosed |
| EP-2723741-A2 | SUBSTITUTED IMIDAZOPYRIDINYL-AMINOPYRIDINE COMPOUNDS | ArQule, Inc. (US) | 2014-04-30 | — | — | EP | disclosed |
| US-20140057896-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2014-02-27 | — | — | US | disclosed |
| WO-2012177844-A2 | SUBSTITUTED IMIDAZOPYRIDINYL-AMINOPYRIDINE COMPOUNDS | ARQULE, INC. (US) | 2012-12-27 | — | — | WO | disclosed |
| US-20120010191-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-20100234409-A1 | Amino cyclopentyl heterocyclic and carbocyclic modulators of chemokine receptor activity | MERCK SHARP & DOHME CORP. | 2010-09-16 | — | — | US | disclosed |
| WO-2008044755-A1 | INK COMPOSITION, INKJET RECORDING INK AND INKJET RECORDING METHOD | FUJIFILM CORPORATION (JP) | 2008-04-17 | — | — | WO | disclosed |
| EP-1753740-A2 | AMINO CYCLOPENTYL HETEROCYCLIC AND CARBOCYCLIC MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Merck & Co., Inc. (US) | 2007-02-21 | — | — | EP | disclosed |
| EP-1633712-A2 | SIX MEMBERED AMINO-AMIDE DERIVATIVES AS ANGIOGENESIS INHIBITORS | Chen, Guoqing Paul (US) | 2006-03-15 | — | — | EP | disclosed |
| WO-2006001958-A2 | AMINO CYCLOPENTYL HETEROCYCLIC AND CARBOCYCLIC MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 2006-01-05 | — | — | WO | disclosed |
| WO-2005000232-A2 | SIX MEMBERED AMINO-AMIDE DERIVATIVES AS ANGIOGENESIS INHIBITORS | CHEN GUOQING PAUL (US) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234409-A1 | Amino cyclopentyl heterocyclic and carbocyclic modulators of chemokine receptor activity | CXCR3, CXCR1, CCR2 | SLC18A3 2937/4885ESR2 349/4885ESR1 817/4885 |
| US-20240366598-A1 | GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR ANTAGONISTS AND USES THEREOF | GIPR, GLP1R, GPR119 | SLC18A3 1326/4885ESR2 692/4885ESR1 435/4885 |
| US-12391663-B2 | Isoindolinone compounds | CYP4F2, AOC2, AOC3 | SLC18A3 3643/4885ESR2 423/4885ESR1 1043/4885 |
| US-20250115581-A1 | SUBSTITUTED PIPERIDINES AS CK1A DEGRADERS | CKS1B, CSNK1A1, CKS2 | SLC18A3 4800/4885ESR2 925/4885ESR1 544/4885 |
| US-20140057896-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | PDXK, BTK, LCK | SLC18A3 4424/4885ESR2 3661/4885ESR1 3255/4885 |
| US-20120010191-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | PDXK, BTK, LCK | SLC18A3 4424/4885ESR2 3661/4885ESR1 3255/4885 |
| US-12617795-B2 | Substituted 6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidines, 5,7-dihydrofuro[3,4-d]pyrimidines, and pyrido[2,3-d]pyrimidines as KCC2 modulators | KCNC1, TRPC6, KCNH2 | SLC18A3 1545/4885ESR2 3512/4885ESR1 4733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.